Posted on 25/11/2009 in Pharmacy Supplier News GlaxoSmithKline has revealed that it plans to work with Gilead to commercialise Viread (tenofovir disoproxil fumarate), a drug for the treatment of chronic hepatitis B (HBV) in adults.
The joint commercialisation efforts of the firms will increase access to the drug to patients who have not yet used it.
As part of the new contract, Gilead will retain the rights to Viread in markets such as Hong Kong, Singapore and Taiwan, while GlaxoSmithKline will be responsible for its registration and commercialisation in China.
"The agreement with Gilead to develop and launch Viread in China builds on [our] strong heritage in hepatitis B and provides an important addition to GlaxoSmithKline's current portfolio in one of our key markets," commented Abbas Hussain, president of emerging markets at GlaxoSmithKline.
GlaxoSmithKline entered into another partnership of this month - that with fellow pharmaceutical firm with Nabi - which will see the two companies manufacture a vaccine to prevent nicotine addiction.Other news stories from 25/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
